Medication info
Linatin Plus Tablet 2.5/1000 mg

Linatin Plus Tablet 2.5/1000 mg

Prescription medicationTabletOral
Ingredient · strength
Linagliptin›2.5mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Jeil Pharmaceutical Co., Ltd.
Appearance
Light pink, biconvex, oval-shaped film-coated tablets
Packaging
PTP - 60 tablets/PTP [10 tablets/PTP × 6]
Approval status
Active

MFDS item code 202203527 · Approved 2022.09.08 · Insurance code 645406230

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be determined for each patient based on their current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 2.5 mg twice daily and metformin 1000 mg twice daily. This medicine should be taken twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior antidiabetic drug treatment whose blood glucose is not adequately controlled with monotherapy, the initial dose of this medicine is 1 tablet of 2.5/500 mg twice daily. The dose may be increased to 1 tablet of 2.5/1000 mg twice daily. 2. Patients inadequately controlled with metformin monotherapy: The initial dose of this medicine should provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Switching from concomitant linagliptin and metformin therapy: Patients switching from concomitant linagliptin and metformin therapy to this medicine should start at their current doses of linagliptin and metformin. 4. Patients inadequately controlled with concomitant metformin and sulfonylurea therapy: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is coadministered with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Use with caution in the following patients). 5. Patients inadequately controlled with concomitant insulin and metformin therapy: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is coadministered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Use with caution in the following patients). No studies have evaluated the safety and efficacy of switching to this medicine in patients previously treated with another oral hypoglycemic agent. Any change in the treatment regimen for type 2 diabetes may alter glycemic control; caution and appropriate monitoring are required. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate [eGFR] 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dosage adjustment. Treatment should not be initiated with this medicine because the starting dose of metformin is 500mg or 850mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not administer to the following patients).

Ingredients

Manufacturer
Jeil Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication helps patients with type 2 diabetes to control their blood sugar by using linagliptin and metformin together. It is used effectively to improve blood sugar levels in conjunction with diet and exercise therapy.

How to take

Adult dose

The dose of this medicine should be determined for each patient based on their current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 2.5 mg twice daily and metformin 1000 mg twice daily. This medicine should be taken twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior antidiabetic drug treatment whose blood glucose is not adequately controlled with monotherapy, the initial dose of this medicine is 1 tablet of 2.5/500 mg twice daily. The dose may be increased to 1 tablet of 2.5/1000 mg twice daily. 2. Patients inadequately controlled with metformin monotherapy: The initial dose of this medicine should provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Switching from concomitant linagliptin and metformin therapy: Patients switching from concomitant linagliptin and metformin therapy to this medicine should start at their current doses of linagliptin and metformin. 4. Patients inadequately controlled with concomitant metformin and sulfonylurea therapy: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is coadministered with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Use with caution in the following patients). 5. Patients inadequately controlled with concomitant insulin and metformin therapy: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is coadministered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Use with caution in the following patients). No studies have evaluated the safety and efficacy of switching to this medicine in patients previously treated with another oral hypoglycemic agent. Any change in the treatment regimen for type 2 diabetes may alter glycemic control; caution and appropriate monitoring are required. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate [eGFR] 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dosage adjustment. Treatment should not be initiated with this medicine because the starting dose of metformin is 500mg or 850mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not administer to the following patients).

Precautions

This medication can cause a serious side effect known as lactic acidosis, so it should not be prescribed to patients with impaired kidney function or problems with heart or liver function. It should particularly be avoided in patients with acute infections, dehydration, severe trauma, shock, pregnant women, and breastfeeding mothers. During the use of this medication, symptoms of hypoglycemia may occur, and if used in conjunction with sulfonylureas or insulin, blood glucose levels should be monitored carefully, and dosages should be adjusted as needed. Regular kidney function tests should be conducted to reduce the risk of drug accumulation and side effects, especially for the elderly or patients with decreased kidney function. Rare skin conditions such as acute pancreatitis or bullous pemphigoid may occur, so if severe abdominal pain or blisters on the skin appear, notify a doctor immediately. The metformin component may lower vitamin B12 levels, so tests to check for vitamin B12 deficiency may be necessary for long-term use. This medication should not be taken with alcohol to avoid increasing the risk of lactic acidosis. If iodinated contrast agents used in radiological tests are administered, this medication should be discontinued before and resumed only after kidney function has returned to normal. It is advisable to temporarily stop this medication before surgery, and it can be resumed after normal meals and recovery of kidney function. Pregnant women or those planning to become pregnant are recommended to use insulin therapy instead of this medication, and it is also safest not to use it while breastfeeding. The safety and efficacy in children under 10 years old or adolescents between 10 and 17 years old have not been established, and therefore it is not recommended. There is insufficient research on the effects on driving or operating machinery, so caution is needed. In case of overdose, serious side effects such as lactic acidosis may occur, so immediate medical treatment should be sought, and hemodialysis may be necessary. This medication should be stored in a tightly sealed container away from moisture and direct sunlight and should not be transferred to another container.

Side effects

  • Lactic acidosis
  • hypoglycemia
  • dysgeusia
  • cough
  • reduced appetite
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
  • vomiting
Show 101 more
  • abdominal pain
  • oral ulcer formation
  • abnormal liver function tests
  • hepatitis
  • pruritus
  • erythema
  • rash
  • bullous pemphigoid
  • severe and disabling arthralgia
  • rhabdomyolysis
  • elevated lipase
  • elevated amylase
  • nasopharyngitis
  • hypersensitivity
  • angioedema
  • urticaria
  • decreased and deficiency of vitamin B12
  • oral ulcers
  • hepatitis
  • liver dysfunction
  • constipation
  • upper abdominal pain
  • enterocolitis
  • bowel obstruction
  • gastritis
  • herpes zoster
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuronitis
  • septicemia
  • pneumonia
  • decreased appetite
  • dehydration
  • hyperglycemia
  • cerebral infarction
  • articulatory disorder
  • Alzheimer's dementia
  • chest pain
  • fever
  • facial swelling
  • fatigue
  • chronic obstructive pulmonary disease
  • asthma
  • diabetic foot
  • skin lesions
  • acute leukemia
  • basal cell carcinoma
  • non-small cell lung cancer
  • malignant pericardial effusion
  • gastric cancer
  • rectal cancer
  • pancreatic cancer
  • meniscus injury
  • pneumoconiosis
  • congestive heart failure
  • angina pectoris
  • acute myocardial infarction
  • unstable angina
  • cardiac arrest
  • diabetic retinopathy
  • acute kidney injury
  • end-stage renal disease
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • dizziness
  • kidney transplant failure
  • pruritus
  • insomnia
  • depression
  • hypertension
  • hearing loss
  • erectile dysfunction
  • goiter
  • anxiety
  • affective disorder
  • contusion
  • bone contusion
  • concussion
  • bone fracture
  • hand fracture
  • laceration
  • palpitations
  • dry eye
  • cataract
  • ocular discomfort
  • allergic conjunctivitis
  • polyuria
  • proteinuria
  • stress urinary incontinence
  • hematuria
  • hypotension
  • flushing
  • hepatic steatosis
  • cholelithiasis
  • benign prostatic hyperplasia
  • confusional state
  • nocturia
  • dermatitis
  • hypertension

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tight container to prevent air and moisture from entering. It is best to maintain a storage temperature between 1 and 25 degrees Celsius at room temperature. Proper storage will help preserve the medication's effectiveness and prevent deterioration.

Appearance and packaging

Appearance

Light pink, biconvex, oval-shaped film-coated tablets

Package unit

PTP - 60 tablets/PTP [10 tablets/PTP × 6]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.